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Abstract. Autosomal dominant optic atrophy (DOA) is the 
most frequent form of hereditary optic atrophy, a disease 
presenting with considerable inter- and intra-familial clinical 
variability. Although a number of mutations in different genes 
are now known to cause DOA, many cases remain undiag-
nosed. In an attempt to identify the underlying genetic defect, 
whole exome sequencing was performed in a 19-year-old male 
that had been affected by isolated DOA since childhood. The 
exome sequencing revealed a pathogenic mutation (p.R468C, 
c.1402C>T) in the AFG3 like matrix AAA peptidase subunit 2 
(AFG3L2) gene, a gene known to be associated with spino-
cerebellar ataxia. The patient did not show any signs other 
than DOA. Thus, the result demonstrates the possibility that 
mutations in the AFG3L2 gene may be a cause of isolated 
autosomal DOA.
Introduction
Autosomal dominant optic atrophy (DOA) is a disorder that 
results from the degeneration of the optic nerve fibers (1). It is 
one of the most prevalent forms of inherited optic neuropathies, 
which are genetic conditions affecting the retinal ganglion 
cells whose axons constitute the optic nerve (2). DOA is an 
important cause of inherited visual failure and occurs equally 
among males and females (1). Its prevalence is estimated to be 
1 per 30,000 worldwide with higher frequencies in Denmark 
(1 per 10,000) due to a founder effect (3). It is generally diag-
nosed during childhood and is characterized by loss of visual 
acuity, dyschromatopsia, visual field defects and optic nerve 
pallor with optic disc excavation (4).
The majority of DOA cases (80%) are isolated 
(non-syndromic) while the remaining (20%) are syndromic (2). 
DOA that presents clinically as an isolated optic neuropathy 
is caused by mutations in OPA1, mitochondrial dynamin like 
GTPase (OPA1) (4), OPA3, outer mitochondrial membrane 
lipid metabolism regulator (OPA3; also associated with 
cataracts) (5), aconitase 2 (ACO2) (6) and transmembrane 
protein 126A (TMEM126A) (7) genes, while syndromic 
DOA forms show greater genetic heterogeneity (8). To date, 
224 genes associated with optic atrophy are listed in the 
Human Phenotype Ontology (HPO) database, the majority 
presenting with neurological symptoms, such as ataxia, mental 
retardation and spastic paraplegia (9). Increasing evidence also 
indicates that other genes, in addition to yet unidentified genes, 
are involved (10). Yet, despite these advancements, more than 
half of DOA patients still await a genetic diagnosis (11). This 
shortcoming may be overcome using whole exome sequencing, 
which has the potential to define the molecular diagnosis of 
patients presenting with a negative result for mutations in the 
OPA1, OPA3, ACO2 and TMEM126A genes.
In the current study, the exome of an Italian patient 
affected by isolated DOA was analyzed. By combining exome 
sequencing with phenotype-driven variant analysis, a hetero-
zygous mutation was identified in the AFG3 like matrix AAA 
peptidase subunit 2 (AFG3L2) gene. Notably, the p.R468C 
(c.1402C>T) mutation was recently described in a family 
exhibiting syndromic DOA co-segregating with mild intel-
lectual disability (11).
Patients and methods
Patient and clinical evaluation. A 19-year-old Italian male was 
admitted to the Pediatric Low Vision Unit of the University 
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Hospital of Padua (Padua, Italy) with suspected optic atrophy. 
The patient had experienced visual difficulties from the age 
of 6, including color vision impairment and photophobia. When 
first examined, at 6 years of age, ophthalmological investiga-
tions revealed a best corrected visual acuity (BCVA) of 0.4 in 
each eye. Farnsworth testing revealed dyschromatopsia and 
fundus examination exhibited bilateral temporal optic nerve 
pallor. Intraocular pressure was within the normal range 
(15 and 13 mmHg in the right and left eye, respectively; normal 
range <18 mmHg). The anterior chamber of the eyes exhibited 
no pathological features.
At the age of 13, photopic and scotopic electroretinography 
tests did not reveal abnormal patterns, whereas visual evoked 
potentials (VEPs) to pattern reversal stimuli documented a 
significant decrease in the amplitude of the P100 wave at 15' 
and 30' angular frequencies. As hereditary optic neuropathy 
was suspected, genetic testing for OPA1 mutations, as well 
as for the mitochondrial mutations associated with Leber 
neuropathy, were performed with negative results.
BCVA worsened from 0.4 in each eye at age 6 to 0.2 in each 
eye at age 15. VEPs were repeated at the age of 17 and exhibited 
considerable worsening of amplitude and waveform.
The individual, who is currently 21-years-old, did not 
demonstrate further clinical deterioration. Furthermore, multi-
focal electroretinogram and electrooculography did not detect 
any alterations.
Whole exome sequencing. Whole blood (3 ml) was collected 
for exome analysis subsequent to obtaining informed consent. 
DNA was extracted using the Qiagen BioRobot DNA 
extraction kit (cat. no. 965162; Qiagen Benelux B.V., Venlo, 
the Netherlands) according to the manufacturer's instruc-
tions and quantified using Nanodrop spectral analysis 
(Thermo Fischer Scientific, Inc., Waltham, MA, USA). DNA 
fragmentation and degradation were evaluated by standard 
agarose gel electrophoresis (100 V, 30 min, 1.5% agarose gel 
in Tris-borate-EDTA buffer). DNA Library preparation and 
whole exon enrichment were performed employing Agilent 
SureSelectXT and Agilent SureSelect Clinical Research 
Exome (Agilent Technologies, Inc., Santa Clara CA, USA). 
Library sequences were obtained using the HiSeq2500 
Illumina Sequencer (125-bp paired end sequence mode). 
Bioinformatics analysis included the following: Next-generation 
sequencing (NGS) reads mapping to whole genomes using the 
Burrows-Wheeler Alignment tool (12) with default param-
eters, polymerase chain reaction (PCR) duplicate removal 
using Picard (http://picard.sourceforge.net), single nucleotide 
polymorphisms and indel calling using the Genome Analysis 
Toolkit (GATK) UnifiedGenotyper (13), variant annotation 
using snpEff (http://snpeff.sourceforge.net) and false positive 
variant filtration using the GATK VariantFiltration module.
Exome sequencing data and reads alignment analysis had 
a mean depth of coverage (DoC) of 122.71x, with 95.7% of the 
captured sequences displaying a mean DoC of 20x. The mean 
DoC calculated for the mutated nucleotides was 69.0x.
An in silico multigene panel of 224 genes listed in the HPO 
database, associated with optic atrophy, was used to filter and 
select genetic variants obtained following exome sequencing 
(gene list is available upon request). Variant classification was 
performed in accordance with the recently published guide-
lines from the American College of Medical Genetics and 
Genomics (14).
Sanger sequencing of the variant p.R468C (c.1402C>T) in the 
AGF3L2 gene. DNA (100 ng) was amplified using a standard 
PCR procedure with a PCR mixture containing 2.5 µl 10X 
concentrated PCR buffer, 0.7 µl 50 mM MgCl2 and 0.75 µl 
10 mM deoxyribonucleotide triphosphates (all from Solis 
BioDyne OÜ, Tartu, Estonia), 0.3 µl of 100 µM forward 
primer (5'-TTTAGCGGTCGGAGATGAAC-3') and 0.3 µl of 
100 µM reverse primer (5'-CTGATGGTGCACTGTTGCTT-3'; 
Integrated DNA Technologies, Coralville, IA, USA), and 
0.5 µl 5 U/µl Hot Start DNA Polymerase (Solis BioDyne OÜ). 
Thermocycling consisted of one cycle of enzyme activation 
(at 95̊C for 15 min), followed by 35 cycles of DNA ampli-
fication (at 95̊C for 45 sec, at 59̊C for 45 sec and at 72̊C 
for 1 min). PCR products were then separated by agarose 
gel electrophoresis (100 V, 30 min, 1.5% agarose gel in 
Tris-borate-EDTA buffer; Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany) and purified with Invisorb Spin 
columns (Invitek Inc., Hayward, CA, USA). PCR-purified 
products were re‑amplified with terminating nucleotides using 
Figure 1. AFG3L2 gene end associated mutations reported in the literature. AFG3L2, AFG3 like matrix AAA peptidase subunit 2.
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Big Dye Terminator v3.1 (Applied Biosystems; Thermo Fisher 
Scientific, Inc.). Sequencing analysis was performed with 
an ABI Prism 3100 Avant automated sequencer (Thermo 
Fisher Scientific, Inc.) equipped with 36‑cm capillary array 
filled with POP6 polymer (Thermo Fisher Scientific, Inc.). 
Electropherograms were analyzed using Sequencing Analysis 
software version 5.1.1 (Applied Biosystems; Thermo Fisher 
Scientific, Inc.).
Results
Whole exome sequencing. Exome sequencing restricted to 
the 224 HPO genes that were associated with isolated and 
syndromic optic atrophy exhibited a mean DoC of 149.46x, 
with 99.00% of the captured sequences displaying a DoC >10x, 
98.07% >20x and 91.56% >50x.
A total of 144 non-synonymous variants were detected 
in the 224 HPO genes that were screened; of these, 19 had 
an allele frequency <5% (data available upon request). Upon 
data analysis and interpretation none of these variants were 
found to be of pathogenic or potentially pathogenic signifi-
cance. However, when extending the genetic analysis across 
the whole exome, a heterozygous p.R468C (c.1402C>T) 
mutation was identified in the AFG3L2 gene. The p.R468C 
mutation is not reported in the public accessible databases 
of human genetics (the Exome Aggregation Consortium, 
Exome Variant Server or 1000 Genome Project). It is located 
in an evolutionary conserved residue and computational 
analysis predicts a potentially damaging effect on the resulting 
protein (PholyPhen2 = 1.00) (phyloP-Vertebrate = 6.25/6.42) 
(phyloP-Primate = 0.56/0.65).
Sanger sequencing. Sanger sequencing analysis confirmed the 
presence of the p.R468C mutation in the patient and excluded 
its presence in the patient's mother. The father was untraceable; 
however, no signs of optic atrophy or cerebellar dysfunctions 
were reported on his behalf.
Discussion
DOA is a highly genetically heterogeneous type of optic 
neuropathy. Current diagnostic genetic testing approaches 
in DOA searches for mutations in OPA1, OPA3, ACO2 and 
TMEM126A, with a diagnostic success rate estimated to 
be ~70% (2). Gene sequencing is either performed by conven-
tional methods, such as Sanger sequencing or by targeted 
capture NGS protocols. However, while single gene sequencing 
(Sanger sequencing) is impractical for clinical practice, due to 
time and budget constraints, the multigene targeted capture 
NGS approach is limiting due to gene selection bias. In addi-
tion, increasing genotype-phenotype associations indicates 
that other genes, in addition to yet unidentified genes, are 
likely to be implicated in DOA. Currently, the genetic testing 
approaches that theoretically guarantee the greatest diagnostic 
success are whole exome and whole genome sequencing.
In the current study, exome sequence analysis and inter-
pretation in the patient revealed that there were no pathogenic 
or likely pathogenic mutations in the four genes typically 
associated with isolated DOA. Subsequently, the analysis was 
extended to include those genes listed in the HPO database 
associated with optic atrophy (primarily syndromic) and 
again the results were negative. Therefore, the whole exome 
was subsequently analyzed using the phenotype-driven 
strategy for exome prioritization of human Mendelian disease 
genes (15,16). Notably, a heterozygous p.R468C (c.1402C>T) 
mutation was identified in exon 11 of the AFG3L2 gene. This 
gene interacts with the protein encoded by the SPG7 gene, 
which is one of the 224 genes listed in the HPO database.
The AFG3L2 gene contains 17 exons spanning 48 kb and 
maps to chromosome 18p11.21 (17). It encodes a 797-amino 
acid protein localized in the mitochondria and it is ubiquitously 
expressed in central and peripheral nerves (17). The AFG3L2 
protein assembles with the homologous protein paraplegin to 
form large proteolytic complexes responsible for mitochondrial 
protein quality control (18,19). Functional studies in neurons 
demonstrated a role of AFG3L2 in axonal development and 
activity of mitochondrial respiratory complexes I and III (19). 
DOA is a mitochondrial disorder, thus reinforcing the possi-
bility of an association between AFG3L2 and this particular 
neuropathy.
The p.R468C mutation in the AFG3L2 gene observed in the 
patient has previously been described in two patients (a father 
and son) with DOA and mild intellectual disability (11). The 
authors, however, did not exclude the possibility of a fortuitous 
association between the two phenotypes (11). In the present 
study, the proband exhibited no signs of intellectual disability. 
However, as the p.R468C mutation in the AFG3L2 gene is 
particularly rare, and given the limited available information 
in previous studies, interfamilial phenotype differences and/or 
penetrance cannot be excluded.
Currently, the majority of mutations in the AFG3L2 gene 
have been reported to be associated with autosomal dominant 
spinocerebellar ataxia 28 (17,20) and autosomal recessive spastic 
ataxia 5 (21,22) (MIM no. 604581). The patient in the present 
study currently exhibits isolated DOA with no signs of ataxia. 
This indicates that different mutations in various locations in 
the AFG3L2 gene may lead to different clinical phenotypes. 
Furthermore, the p.R468C mutation is located in exon 11, while 
all known ataxia-causing mutations, except one, are located in 
exons 15 and 16 of AFG3L2 (23,24) (Fig. 1). However, the muta-
tion may be mild and/or cause late-onset ataxia or extra-ocular 
signs (11), thus requiring ongoing surveillance of the patient.
In conclusion, the current study identified, to the best of 
our knowledge, the first case of non‑syndromic isolated optic 
atrophy potentially associated with a heterozygous pathogenic 
mutation in the AFG3L2 gene. Screening for mutations in this 
gene may facilitate with characterizing the genotype-pheno-
type association of AFG3L2 genetic variations in those 
patients without a genetic diagnosis of DOA. Using whole 
exome sequencing in clinical practice will further identify the 
disease aetiology of DOA, ideally facilitating genetic diag-
nosis, as well as the design of future treatment strategies.
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